PTC Therapeutics Inc. (PTCT)

43.08
0.11 0.26
NASDAQ : Health Technology
Prev Close 42.97
Open 42.70
Day Low/High 42.28 / 43.33
52 Wk Low/High 27.53 / 48.99
Volume 55.76K
Avg Volume 458.70K
Exchange NASDAQ
Shares Outstanding 58.95M
Market Cap 2.54B
EPS -2.80
P/E Ratio N/A
Div & Yield N.A. (N.A)
August 24th Options Now Available For PTC Therapeutics (PTCT)

August 24th Options Now Available For PTC Therapeutics (PTCT)

Investors in PTC Therapeutics Inc saw new options become available today, for the August 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new August 24th contracts and identified one put and one call contract of particular interest.

August 10th Options Now Available For PTC Therapeutics (PTCT)

August 10th Options Now Available For PTC Therapeutics (PTCT)

Investors in PTC Therapeutics Inc saw new options begin trading today, for the August 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new August 10th contracts and identified one put and one call contract of particular interest.

August 3rd Options Now Available For PTC Therapeutics (PTCT)

August 3rd Options Now Available For PTC Therapeutics (PTCT)

Investors in PTC Therapeutics Inc saw new options become available today, for the August 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new August 3rd contracts and identified one put and one call contract of particular interest.

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

Sarepta Shares Keep Climbing and PTC Therapeutics Bounces Back

Sarepta adds another 7% on top of nearly 40% gains on Tuesday following good results for a new gene therapy.

Biotech Firm Sarepta Surges 40% on Positive Test Results

Biotech Firm Sarepta Surges 40% on Positive Test Results

But rival firm PTC Therapeutics tumbles nearly 31% on the news.

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries

The Dow and S&P 500 declined Monday as investors react to last week's escalation in the ongoing trade war between Washington and Beijing.

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

PTC Shares Skyrocket on Positive Data for Spinal Muscular Atrophy Drug

Updated interim data from a study of risdiplam were presented June 16 at the 22nd Annual SMA Researcher Meeting.

July 13th Options Now Available For PTC Therapeutics (PTCT)

Investors in PTC Therapeutics Inc saw new options become available today, for the July 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new July 13th contracts and identified one put and one call contract of particular interest.

Notice To Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval Of Derivative Settlement On Behalf Of PTC Therapeutics, Inc.

Notice To Current PTC Stockholders: Rosen Law Firm Announces Preliminary Approval Of Derivative Settlement On Behalf Of PTC Therapeutics, Inc.

On April 17, 2018, PTC Therapeutics, Inc. (NASDAQGS:PTCT) ("PTC" or the "Company"), in its capacity as a nominal defendant, entered into a Stipulation of Settlement (the "Stipulation") in the above-captioned shareholder derivative action -- in which three...

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.

Notable Monday Option Activity: PTCT, OLN, ICPT

Notable Monday Option Activity: PTCT, OLN, ICPT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,147 contracts have traded so far, representing approximately 314,700 underlying shares. That amounts to about 46.8% of PTCT's average daily trading volume over the past month of 672,560 shares.

Notable Monday Option Activity: PTCT, DG, IDCC

Notable Monday Option Activity: PTCT, DG, IDCC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 6,631 contracts has been traded thus far today, a contract volume which is representative of approximately 663,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 75.2% of PTCT's average daily trading volume over the past month, of 882,305 shares.

Short Interest Increases 19% For PTCT

Short Interest Increases 19% For PTCT

The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 1,353,958 share increase in total short interest for PTC Therapeutics Inc , to 8,436,994, an increase of 19.12% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Flexion Shares Continue Rise After FDA Approval -- Biotech Movers

Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.

Noteworthy Wednesday Option Activity: PTCT, SNX, UPL

Noteworthy Wednesday Option Activity: PTCT, SNX, UPL

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 4,409 contracts has been traded thus far today, a contract volume which is representative of approximately 440,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 69.6% of PTCT's average daily trading volume over the past month, of 633,365 shares.

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

Jim Cramer says some sellers are making a big mistake by not giving top-notch CEOs the benefit of the doubt despite earnings upheaval.

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Jim Cramer is bullish on Hertz Global Holdings, Honeywell, PetMed Express, and Allergan.

Commit To Buy PTC Therapeutics At $15, Earn 33.1% Annualized Using Options

Commit To Buy PTC Therapeutics At $15, Earn 33.1% Annualized Using Options

Investors considering a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $18.52/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $15 strike, which has a bid at the time of this writing of $2.80.

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.

Short Interest In PTC Therapeutics Expands By 20.8%

The most recent short interest data has been released for the 05/15/2017 settlement date, which shows a 1,263,458 share increase in total short interest for PTC Therapeutics Inc , to 7,350,209, an increase of 20.76% since 04/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc have crossed above the average analyst 12-month target price of $12.40, changing hands for $12.59/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Commit To Buy PTC Therapeutics At $8, Earn 26% Annualized Using Options

Investors eyeing a purchase of PTC Therapeutics Inc stock, but tentative about paying the going market price of $8.55/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2018 put at the $8 strike, which has a bid at the time of this writing of $1.70.

Biotech Premarket Movers: Seres, PTC, Inovio

Biotech Premarket Movers: Seres, PTC, Inovio

Seres Therapeutics, PTC Therapeutics and Inovio Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Biotech Premarket Movers: PTC, Teligent, Minerva

Biotech Premarket Movers: PTC, Teligent, Minerva

PTC Therapeutics, Teligent and Minerva Neurosciences were among the biotech stock movers in premarket trading on Monday.

Relative Strength Alert For PTC Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D (Sell)